CTMX
NASDAQCytomX Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks44-94%
2025-10-262026-04-19
Mix2990d
- Insider9(31%)
- SEC Filings7(24%)
- Other6(21%)
- Earnings3(10%)
- Offering2(7%)
- Leadership1(3%)
- Other1(3%)
Latest news
25 items- SECSEC Form PRE 14A filed by CytomX Therapeutics Inc.PRE 14A - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- INSIDERSEC Form 4 filed by Chu Yu-Waye4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Mccarthy Sean A.4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Belvin Marcia4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Ogden Christopher4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- SECSEC Form 8-K filed by CytomX Therapeutics Inc.8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form 424B5 filed by CytomX Therapeutics Inc.424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additiona
- SECSEC Form 424B5 filed by CytomX Therapeutics Inc.424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering m
- SECSEC Form S-3ASR filed by CytomX Therapeutics Inc.S-3ASR - CytomX Therapeutics, Inc. (0001501989) (Filer)
- ANALYSTCytomX Therapeutics upgraded by Analyst with a new price targetAnalyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00
- PRCytomX Therapeutics Announces 2025 Financial Results and Provides Business Update- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M
- SECCytomX Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form 10-K filed by CytomX Therapeutics Inc.10-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics
- SECSEC Form SCHEDULE 13G filed by CytomX Therapeutics Inc.SCHEDULE 13G - CytomX Therapeutics, Inc. (0001501989) (Subject)
- PRCytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- INSIDERChief Business Officer Lester Rachael was granted 20,000 shares (SEC Form 4)4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERChief Medical Officer Chu Yu-Waye was granted 75,000 shares, increasing direct ownership by 55% to 210,725 units (SEC Form 4)4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSVP, Chief Scientific Officer Belvin Marcia was granted 60,000 shares, increasing direct ownership by 22% to 332,252 units (SEC Form 4)4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)